![](https://www.techmonitor.ai/wp-content/uploads/sites/29/2022/07/Hexaware-whitepaper_Accelerating-adoption-of-decentralized-trials-in-a-post-COVID-19-era-1-1-copy-scaled.jpg)
Accelerating adoption of decentralized trials in a post COVID-19 era
By Hexaware-Technologies
The impact of the COVID-19 pandemic on the operations of clinical trials across the globe is grave. Pharma and clinical research companies are trying to mitigate the challenges. The operations in the clinical trial space have stalled due to the fear of cross-infection. The healthcare industry has a two-pronged strategy to mitigate the effects of the pandemic a) assessment of the current situation b) the optimal way forward.
![](https://www.techmonitor.ai/wp-content/uploads/sites/29/2022/07/Hexaware-whitepaper_Accelerating-adoption-of-decentralized-trials-in-a-post-COVID-19-era-1-1-copy-scaled.jpg)